CareDx, Inc. (FRA:1K9)

Germany flag Germany · Delayed Price · Currency is EUR
16.26
+0.27 (1.69%)
Last updated: Jan 5, 2026, 8:05 AM CET
-25.23%
Market Cap757.43M
Revenue (ttm)305.12M
Net Income (ttm)60.05M
Shares Outn/a
EPS (ttm)1.04
PE Ratio12.61
Forward PE16.81
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume1
Open16.26
Previous Close15.99
Day's Range16.26 - 16.26
52-Week Range9.83 - 24.24
Betan/a
RSI40.12
Earnings DateFeb 27, 2026

About CareDx

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to typ... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 1998
Employees 650
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 1K9
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

CareDx and 10x Genomics to Launch ImmuneScape Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value health...

4 days ago - Wallstreet:Online

CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinical...

4 days ago - Business Wire

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healt...

15 days ago - Wallstreet:Online

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinica...

15 days ago - Business Wire

CareDx Provides Notice of Proposed Derivative Settlement

CareDx, Inc. (Nasdaq: CDNA) today provided notice of proposed settlement of derivative actions and settlement hearing. UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA JEFFREY EDELMAN, JAY...

23 days ago - Wallstreet:Online

CareDx Provides Notice of Proposed Derivative Settlement

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) today provided notice of proposed settlement of derivative actions and settlement hearing. UNITED STATES DISTRICT COURT NORTHERN DISTRICT...

23 days ago - Business Wire

Crypto.com partners with ERShares and Signal Markets on prediction market intelligence platform

Crypto.com | Derivatives North America (CDNA), a CFTC-registered exchange and clearinghouse affiliated with Crypto.com, has announced a strategic collaboration with … Continue reading The post Crypto....

26 days ago - Finbold

SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiat...

6 weeks ago - Business Wire

SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation

CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transp...

6 weeks ago - Wallstreet:Online

CareDx to Participate in Upcoming Investor Conferences

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

2 months ago - Business Wire

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization ...

2 months ago - Business Wire

CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization ...

2 months ago - Business Wire

CDNA: BTIG Raises Price Target to $25, Maintains Buy Rating | CDNA Stock News

CDNA: BTIG Raises Price Target to $25, Maintains Buy Rating | CDNA Stock News

2 months ago - GuruFocus

After-Hours Gainers: VCYT, RIGL, NPCE, CDNA, And FBLG Post Notable Moves Following Q3 Results

(RTTNews) - Several healthcare and biotech names posted strong after-hours gains on Tuesday following the release of third-quarter earnings and updated guidance for the remainder of 2025. The session ...

2 months ago - Nasdaq

CareDx Inc (CDNA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance

CareDx Inc (CDNA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance

2 months ago - GuruFocus

CareDx, Inc (CDNA) Q3 2025 Earnings Call Transcript

CareDx, Inc (CDNA) Q3 2025 Earnings Call November 4, 2025 4:30 PM ESTCompany ParticipantsTina JacobsenJohn Hanna - President, CEO & DirectorNathan Smith...

2 months ago - Seeking Alpha

Q3 2025 CareDx Inc Earnings Call Transcript

Q3 2025 CareDx Inc Earnings Call Transcript

2 months ago - GuruFocus

CareDx (CDNA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for CareDx (CDNA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compar...

2 months ago - Nasdaq

CareDx Inc (CDNA) Q3 2025 Earnings: EPS of $0. ...

CareDx Inc (CDNA) Q3 2025 Earnings: EPS of $0.03 Beats Estimate, Revenue Surpasses Expectations at $100.1 Million

2 months ago - GuruFocus

CareDx Announces Third Quarter 2025 Financial Results

CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company — a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthc...

2 months ago - Wallstreet:Online

CareDx Announces Third Quarter 2025 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company — a leading precision medicine company focused on the discovery, development and commercialization of clinically...

2 months ago - Business Wire

CareDx Q3 2025 Earnings Preview

2 months ago - Seeking Alpha

CareDx Inc (CDNA) Q3 2025 Earnings Report Preview: What To Expect

CareDx Inc (CDNA) Q3 2025 Earnings Report Preview: What To Expect

2 months ago - GuruFocus